Axalbion SA

Swiss Biotech Association

Not a member

Axalbion is a clinical-stage pharmaceutical company developing TRPM8 agonists for the treatment of chronic cough. Axalbion’s s strategy is to develop its lead compound AX-8 up-to Phase 2b to show clinical proof of concept across a representative patient population.

http://www.axalbion.com/

Location

PSE C, 1015 Lausanne, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2017
Number of employees in Switzerland

1-9

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

Solvias AG

Solvias is a contract research, development & manufacturing
We offer early phase development of small molecules API by process R&D and GMP-manufacturing integrated with high through-put screening, solid state and a wide ligand portfolios for catalytic transformations and analytical services.
Kaiseraugst

Member

Porton Pharmaceutical Chemicals GmbH

Porton Pharma is a a leading CDMO with operations and commercial offices across the US, EU and China. Porton Pharma provides global pharmaceutical companies with innovative, reliable and end-to-end process R&D and manufacturing services across small molecules, dosage forms and biologics.
6039 Root

Member

Bavarian Nordic Berna GmbH

Bavarian Nordic is a fully integrated vaccine company focused on the development, manufacturing and commercialization of life-saving vaccines. Our manufacturing site for oral vaccines is located in Thörishaus, 15 km southwest of Bern.
3174 Thörishaus

Member